Brief: Clearside Biomedical Announces Positive Results In Oasis Phase 1/2A Clinical Trial Of Suprachoroidal Cls-Ax In Wet AMD Patients

Clearside Biomedical,

09/11/2022 12:55

Nov 9 (Reuters) - Clearside Biomedical Inc  CLSD.O :
    * CLEARSIDE BIOMEDICAL ANNOUNCES POSITIVE RESULTS IN SAFETY,
DURABILITY AND BIOLOGIC EFFECT IN OASIS PHASE 1/2A CLINICAL
TRIAL OF SUPRACHOROIDAL CLS-AX (AXITINIB INJECTABLE SUSPENSION)
IN WET AMD PATIENTS
    * CLEARSIDE BIOMEDICAL -PRIMARY SAFETY ENDPOINT ACHIEVED AT
ALL
TIMEPOINTS WITH ALL DOSES WELL-TOLERATED, NO TREATMENT RELATED
OR SERIOUS ADVERSE EVENTS
    * CLEARSIDE BIOMEDICAL INC - FINAL 6-MONTH DATA FROM
EXTENSION
STUDY EXPECTED IN Q1 2023
    * CLEARSIDE BIOMEDICAL INC - EXPECT TO INITIATE PHASE 2
CLINICAL
TRIAL IN Q1 2023
    * CLEARSIDE BIOMEDICAL INC - COHORTS 3, 4 SHOWED PROMISING
SIGNS
OF DURABILITY, BIOLOGIC EFFECT, AND A MEANINGFUL REDUCTION IN
TREATMENT BURDEN IN STUDY

Source text for Eikon:  ID:nGNX7K03SF 
Further company coverage:  CLSD.O 
 ((Reuters.Briefs@thomsonreuters.com;))